PTPI
Petros Pharmaceuticals, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$0.01
+20.00%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | — | — | 5.1M | 5.8M | 6.0M |
| Cost of Revenue | — | — | 1.2M | 1.6M | 2.3M |
| Gross Profit | — | — | 3.9M | 4.2M | 3.7M |
| Operating Expenses | |||||
| R&D Expense | — | — | 2.6M | 2.4M | 1.7M |
| SG&A Expense | 2.4M | 4.6M | 8.7M | 9.3M | 12.2M |
| General & Admin Expense | — | — | — | — | — |
| Selling & Marketing Expense | — | — | — | — | — |
| Other Expenses | 990.7K | — | 10.2M | 6.1M | 9.7M |
| Total Operating Expenses | 3.4M | 4.6M | 21.6M | 17.8M | 23.6M |
| Cost and Expenses | 2.4M | 4.6M | 22.8M | 19.4M | 25.9M |
| Operating Income (EBIT) | (3.4M) | (4.6M) | (17.7M) | (13.6M) | (19.9M) |
| Non-Operating | |||||
| Interest Income | 192.4K | 256.9K | 371.8K | 515.3K | 14.2K |
| Interest Expense | — | — | 560.9K | 536.1K | 596.0K |
| Net Interest Income | 160.4K | 256.9K | (189.1K) | (20.8K) | (581.8K) |
| Other Non-Op Income/Expense | 196.0K | 141.3K | 3.4M | 5.5M | (121.8K) |
| Non-Operating Income (excl Interest) | (163.1K) | (141.3K) | (3.9M) | (6.0M) | (474.2K) |
| EBT (Pre-Tax Income) | (3.2M) | (4.5M) | (14.3M) | (8.2M) | (20.0M) |
| Income Tax Expense | — | — | — | — | — |
| Bottom Line | |||||
| Net Income | (3.2M) | 1.9M | (14.3M) | (8.2M) | (20.0M) |
| Earnings from Cont. Ops | (3.2M) | (4.5M) | (14.3M) | (8.2M) | (20.0M) |
| Earnings from Discont. Ops | 7.0M | 6.4M | — | — | — |
| Bottom Line Net Income | 5.1M | (43.7M) | (26.8M) | (13.8M) | (20.0M) |
| Per Share | |||||
| Basic EPS | $8.51 | ($1.56) | ($3.34) | ($6.35) | ($9.68) |
| Diluted EPS | $8.51 | ($1.56) | ($3.34) | ($6.35) | ($9.68) |
| Revenue Per Share | $0.00 | $0.00 | $0.64 | $4.53 | $2.89 |
| Shares | |||||
| Basic Shares Outstanding | 47.4M | 280.7M | 8.0M | 1.3M | 2.1M |
| Diluted Shares Outstanding | 47.4M | 280.7M | 8.0M | 2.2M | 2.1M |
| Profitability Metrics | |||||
| EBITDA | (2.5M) | (4.5M) | (10.8M) | (4.2M) | (13.7M) |
| D&A | 707.8K | — | 2.9M | 3.4M | 5.7M |
| EBIT | (2.2M) | (4.5M) | (13.8M) | (7.6M) | (19.4M) |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026